MK-2225

BIOLOGICAL2 trials

Sponsors

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA, Merck Sharp & Dohme LLC

Conditions

Systemic SclerosisSystemic Sclerosis With and Without Interstitial Lung Disease

Phase 1

A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

TerminatedNCT04948554

Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USASystemic Sclerosis With and Without Interstitial Lung Disease

Start: 2023-03-10End: 2023-10-18Updated: 2023-11-24

A Study of MK-2225 in Healthy Participants (MK-2225-003)

CompletedNCT06643390

Merck Sharp & Dohme LLCSystemic Sclerosis

Start: 2023-11-21End: 2025-07-14Updated: 2025-07-29